TLDR Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.
The document reports a case of successful treatment of a rare form of lichen planopilaris (LLPP) using Ixekizumab, an anti-IL-17A/F antibody. A 30-year-old woman with LLPP involving the scalp and forehead achieved complete hair regrowth within 12 weeks of treatment, with sustained efficacy and no side effects for 12 months. Previous treatments had failed to produce satisfactory results. This case suggests that Ixekizumab could be a viable first-line therapy for LPP and its variants, warranting further multicenter trials to confirm its benefits.
Cited in this study
5 / 5 results
10 citations
,
July 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
95 citations
,
December 2016 in “Journal of The American Academy of Dermatology” Treatments for permanent hair loss from scarring aim to stop further loss, not regrow hair, and vary by condition, with partial success common.
47 citations
,
July 2014 in “Journal of Dermatological Treatment” Most treatments for lichen planopilaris were found to be generally unsatisfactory.
23 citations
,
March 2010 in “Journal of The American Academy of Dermatology” Effective treatments for lichen planopilaris are unclear due to inconsistent results and a lack of strong research evidence.
113 citations
,
July 2007 in “Journal of the American Academy of Dermatology” The study found that steroids and tetracycline helped treat active Lichen planopilaris, and hair transplants were good for later stages.
